Factors with conformational effects on haemostatic serpins: Implications in thrombosis

Thrombosis and Haemostasis

Volumn 98, Issue 3, 2007, Pages 557-563

  Hernández Espinosa, David ^a   Ordóñez, Adriana ^a   Vicente, Vicente ^a   Corral, Javier ^a  

^a UNIVERSITY OF MURCIA   (Spain)

Author keywords

Antithrombin; Liver; SERPINs; Venous thrombosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; ASPARAGINASE; HEPARIN COFACTOR II; POLYMER; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

CONFORMATIONAL TRANSITION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; HEMOSTASIS; HIGH TEMPERATURE; HUMAN; HYPERCOAGULABILITY; HYPERLIPIDEMIA; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN STRUCTURE; REVIEW; RISK FACTOR; VEIN THROMBOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTITHROMBINS; ASPARAGINASE; FATTY LIVER; FEVER; GENETIC PREDISPOSITION TO DISEASE; HEMOSTASIS; HUMANS; MUTATION; PROTEIN CONFORMATION; RISK FACTORS; SERPINS; VENOUS THROMBOSIS;

EID: 34548702447     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-02-0152     Document Type: Review

References (85)

1. Irving JA, Pike RN, Lesk AM, et al. Phylogeny of the serpin superfamily: implications of patterns of amino acid conservation for structure and function. Genome Res 2000; 10: 1845-1864.
2. Rawlings ND, Tolle DP, Barrett AJ. Evolutionary families of peptidase inhibitors. Biochem J 2004; 378: 705-716.
3. Silverman GA, Bird PI, Carrell RW, et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-33296.
4. Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-926.
5. Irving JA, Shushanov SS, Pike RN, et al. Inhibitory activity of a heterochromatin-associated serpin (MENT) against papain-like cysteine proteinases affects chromatin structure and blocks cell proliferation. J Biol Chem 2002; 277: 13192-13201.
6. Ligoxygakis P, Roth S, Reichhart JM. A serpin regulates dorsal-ventral axis formation in the Drosophila embryo. Curr Biol 2003; 13: 2097-2102.
7. Pak SC, Kumar V, Tsu C, et al. SRP-2 is a cross-class inhibitor that participates in postembryonic development of the nematode Caenorhabditis elegans: initial characterization of the clade L serpins. J Biol Chem 2004; 279: 15448-15459.
8. Levashina EA, Langley E, Green C, et al. Constitutive activation of toll-mediated antifungal defense in serpin-deficient Drosophila. Science 1999; 285: 1917-1919.
9. Ray CA, Black RA, Kronheim SR, et al. Viral inhibition of inflammation: cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme. Cell 1992; 69: 597-604.
10. Van Gent D, Sharp P, Morgan K, et al. Serpins: structure, function and molecular evolution. Int J Biochem Cell Biol 2003; 35: 1536-1547.
11. Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation system as a molecular machine. Bioessays 2003; 25: 1220-1228.
12. Kottke-Marchant K, Duncan A. Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326-1336.
13. Rezaie AR. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa. J Biol Chem 1998; 273: 16924-16827.
14. Huntington JA. Mechanisms of glycosaminoglycan activation of the serpins in hemostasis. J Thromb Haemost 2003; 1: 1535-1549.
15. Ishiguro K, Kojima T, Kadomatsu K, et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873-878.
16. Pike RN, Buckle AM, le Bonniec BF, et al. Control of the coagulation system by serpins. Getting by with a little help from glycosaminoglycans. FEBS J 2005; 272: 4842-4851.
17. Han X, Fiehler R, Broze GJ Jr. Isolation of a protein Z-dependent plasma protease inhibitor. Proc Natl Acad Sci U S A; 1998; 95: 9250-9255.
18. Han X, Fiehler R, Broze GJ Jr. Characterization of the protein Z-dependent protease inhibitor. Blood 2000; 96: 3049-3055.
19. Heeb MJ, Cabral KM, Ruan, L. Down-regulation of factor IXa in the factor Xase complex by protein Z-dependent protease inhibitor. J Biol Chem 2005; 280: 33819-33825.
20. Tollefsen DM. Heparin cofactor II deficiency. Arch Pathol Lab Med 2002; 126: 1394-1400.
21. Corral J, Gonzalez-Conejero R, Soria JM, et al. A nonsense polymorphism in the protein Z-dependent protease inhibitor increases the risk for venous thrombosis. Blood 2006; 108: 177-183.
22. Water N, Tan T, Ashton F, et al. Mutations within the protein Z-dependent protease inhibitor gene are associated with venous thromboembolic disease: a new form of thrombophilia. Br J Haematol 2004; 127: 190-194.
23. Broze GJ Jr. Protein Z-dependent regulation of coagulation. Thromb Haemost 2001; 86: 8-13.
24. Corral J, González-Conejero R, Hernández-Espinosa D, et al. Protein Z/Z-dependent protease inhibitor (PZ/ZPI) anticoagulant system and thrombosis. Br J Haematol 2007; 137: 99-108.
25. Corral J, Aznar J, Gonzalez-Conejero R, et al. Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation 2004; 110: 1303-1307.
26. Razzari C, Martinelli I, Bucciarelli P, et al. Polymorphisms of the protein Z-dependent protease inhibitor (ZPI) gene and the risk of venous thromboembolism. Thromb Haemost 2006; 95: 909-910.
27. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 2006; 4: 101-116.
28. Geiger M, Zechmeister-Machhart M, Uhrin P, et al. Protein C inhibitor (PCI). Immunopharmacology 1996; 32: 53-56.
29. Huntington JA, Pannu NS, Hazes B, et al. A 2.6 A structure of a serpin polymer and implications for conformational disease. J Mol Biol 1999; 293: 449-455.
30. Marszal E, Shrake A. Serpin crystal structure and serpin polymer structure. Arch Biochem Biophys 2006; 453: 123-129.
31. Carrell RW, Lomas DA. Conformational disease. Lancet 1997; 350: 134-138.
32. Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002; 3: 759-768.
33. Lomas DA. Molecular mousetraps, alpha1-antitrypsin deficiency and the serpinopathies. Clin Med 2005; 5: 249-257.
34. Carrell RW, Lomas DA. Alpha1-antitrypsin deficiency. A model for conformational diseases. N Engl J Med 2002; 346: 45-53.
35. Miranda E, Lomas DA. Neuroserpin: a serpin to think about. Cell Mol Life Sci 2006; 63: 709-722.
36. Benetazzo MG, Gile LS, Bombieri C, et al. Alpha 1-antitrypsin TAQ I polymorphism and alpha 1-antichymotrypsin mutations in patients with obstructive pulmonary disease. Respir Med 1999; 93: 648-654.
37. Fay A, Abinun M. Current management of hereditary angio-oedema (C'1 esterase inhibitor deficiency). J Clin Pathol 2002; 55: 266-270.
38. Corral J, Vicente V, Carrell RW. Thrombosis as a conformational disease. Haematologica 2005; 90: 238-246.
39. Carrell RW, Huntington JA, Mushunje A, et al. The conformational basis of thrombosis. Thromb Haemost 2001; 86: 14-22.
40. Stein PE, Carrell RW. What do dysfunctional serpins tell us about molecular mobility and disease? Nat Struct Biol 1995; 2: 96-113.
41. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593.
42. Amderson FA Jr, Wheeler HB, Goldberg RJ, et al. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 591-595.
43. Nordstrom M, Lindblad B, Bergqvist D, et al. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-160.
44. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999; 159: 445-453.
45. Laffan M, Tuddenham E. Science, medicine, and the future: assessing thrombotic risk. Br Med J 1998; 317: 520-523.
46. Egeberg O. Thrombophilia caused by inheritable deficiency of blood antithrombin. Scand J Clin Lab Invest 1965; 17: 92.
47. Bayston T, Lane D. Imperial College of London. Antithrombin mutation database. http://wwwfom.sk.med.ic.ac.uk/medicine/about/divisions/is/ haemo/coag/antithrombin.
48. OMIM. http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=107300.
49. HGMD. http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SERPINC1.
50. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231.
51. Han X, Huang ZF, Fiehler R, et al. The protein Z-dependent protease inhibitor is a serpin. Biochemistry 1999; 38: 11073-11078.
52. Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94: 3388-3396.
53. O'Reilly MS, Pirie-Shepherd S, Lane WS, et al. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science 1999; 285: 1926-1928.
54. Zhang W, Swanson R, Xiong Y, et al. Antiangiogenic antithrombin blocks the heparan sulfate-dependent binding of proangiogenic growth factors to their endothelial cell receptors. J Biol Chem 2006; 281: 37302-37310.
55. Corral J, Huntington JA, Gonzalez-Conejero R, et al. Mutations in the shutter region of antithrombin result in formation of disulfide-linked dimers and severe venous thrombosis. J Thromb Haemost 2004; 2: 931-939.
56. Picard V, Dautzenberg MD, Villoutreix BO, et al. Antithrombin F229L: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood 2003; 102: 919-925.
57. Bruce D, Perry DJ, Borg J-Y, et al. Thromboembolic diseases due to conformational changes of antithrombin Rouen VI (187 Asnà Asp). J Clin Invest 1994; 94: 2265-2274.
58. Beauchamp NJ, Pike RN, Daly M, et al. Antithrombins Wibble and Wobble (T85M/K): archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood 1998; 92: 2696-2706.
59. Kanagawa Y, Shigekiyo T, Aihara K, et al. Molecular mechanism of type I congenital heparin cofactor (HC) II deficiency caused by a missense mutation at reactive P2 site: HC II Tokushima. Thromb Haemost 2001; 85: 101-107.
60. Fitches AC, Lewandowski K, Olds RJ. Creation of an additional glycosylation site as a mechanism for type I antithrombin deficiency. Thromb Haemost 2001; 86: 1023-1027.
61. Ozawa T, Takikawa Y, Niiya K, et al. Antithrombin Morioka (Cys 95-Arg): a novel missense mutation causing type I antithrombin deficiency. Thromb Haemost 1997; 77: 403.
62. Emmerich J, Vidaud D, Alhenc-Gelas M, et al. Three novel mutations of antithrombin inducing high-molecular-mass compounds. Arterioscler Thromb 1994; 14: 1958-1965.
63. Picard V, Bauters A, Khairy M, et al. Conformational Asn187Asp/Lys antithrombin variants and thrombosis. Clinical and biological features in 13 new heterozygotes. Thromb Haemost 2005; 93: 57-62.
64. Lindo VS, Kakkar W, Learmonth M, et al. Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin. Br J Haematol 1995; 89: 589-601.
65. Verpy E, Biasotto M, Brai M, et al. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angioedema. Am J Hum Genet 1996; 59: 308-319.
66. Davis AE, Aulak K, Parad RB, et al. C1 inhibitor hinge region mutations produce dysfunction by different mechanisms. Nature Genet 1992; 1: 354-358.
67. Skriver K, Radziejewska E, Siebermann JA, et al. CpG mutations in the reactive site of human C1 inhibitor. J Bio Chem 1989; 264: 3066-3071.
68. Siddique Z, McPhaden AR, Whaley K. Type II hereditary angio-oedema associated with two mutations in one allele of the C1-inhibitor gene around the reactive-site coding region. Hum Hered 1992; 42: 298-301.
69. Levy NJ, Ramesh N, Cicardi M, et al. Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene. Proc Nat Acad Sci 1990; 87: 265-268.
70. Verpy E, Couture-Tosi E, Eldering E, et al. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function. J Clin Invest 1995; 95: 350-359.
71. Kalmar L, Bors A, Farkas H, et al. Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema. Hum Mutat 2003; 22: 498.
72. Huber R, Carrell RW. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry 1989; 28: 8951-8966.
73. Miura O, Sugahara Y, Aoki N. Hereditary alpha 2-plasmin inhibitor deficiency caused by a transport-deficient mutation (alpha 2-PI-Okinawa). Deletion of Glu137 by a trinucleotide deletion blocks intracellular transport. J Biol Chem 1989; 264: 18213-18219.
74. The Serpin Database. Structural medicine. http://www-structmed.cimr.cam.ac.uk/Serpins/serp_regions/table2.html.
75. Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochim Biophys Acta 2001; 1535: 221-235.
76. Mushunje A, Evans G, Brennan SO, et al. Latent antithrombin and its detection, formation and turnover in the circulation. J Thromb Haemost 2004; 2: 2170-2177.
77. Corral J, Rivera J, Martínez C, et al. Detection of conformational transformation of antithrombin in blood by crossed immunoelectrophoresis: New application for a classical method. Effect of temperature in plasmatic antithrombin; role in senescence of antithrombin and thrombosis. J Lab Clin Med 2003; 142: 298-315.
78. Nar H, Bauer M, Stassen JM, et al. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J Mol Biol 2000; 297: 683-695.
79. Zhou A, Stein PE, Huntington JA, et al. Serpin polymerization is prevented by a hydrogen bond network that is centered on his-334 and stabilized by glycerol. J Biol Chem 2003; 278: 15116-15122.
80. De Stefano V, Sora F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005; 3: 1985-1992.
81. Hernandez-Espinosa D, Minano A, Martinez C, et al. L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases. Am J Pathol 2006: 169: 142-153.
82. Bell H, Odegaard OR, Andersson T, et al. Protein C in patients with alcoholic cirrhosis and other liver diseases. J Hepatol 1992; 14: 163-167.
83. Castro MA, Goodwin TM, Shaw KJ, et al. Disseminated intravascular coagulation and antithrombin III depression in acute fatty liver of pregnancy. Am J Obstet Gynecol 1996; 174: 211-216.
84. Hernandez-Espinosa D, Ayala I, Castells MT, et al. Intracellular retention of hepatic serpins caused by severe hyperlipidemia. Liver Int 2006; 26: 708-715.
85. Hernandez-Espinosa D, Mota R, Miñano A, et al. In vivo effects of hyperthermia on the functional and conformational characteristics of antithrombin. J Thromb Haemost 2007; 5: 963-970.